---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-014216"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:15:02.619020+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tonix sets Tonmya WAC at $1,860/month; appoints Ganesh Kamath as Head of Market Access

## Summary
- Tonmya (cyclobenzaprine HCl sublingual tablets) approved Aug 15, 2025 for fibromyalgia; launch expected Q4 2025.
- Wholesale acquisition cost (WAC) set at $1,860/month for 60-count supply; geriatric/mild hepatic: $930/month for 30-count.
- Ganesh Kamath appointed Head of Market Access effective Sept 29, 2025; brings 25+ years experience from Bayer, Hutchmed, CuriaGlobal.
- Kamath will lead pricing, contracting, and payer engagement for Tonmya launch and pipeline.
- First new fibromyalgia prescription therapy in over 15 years; Tonix also markets two acute migraine treatments.

## SEC filing metadata
- accession: 0001999371-25-014216
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/0001999371-25-014216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/tnxp-8k_093025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-014216
- JSON: https://secwatch.observer/filing/0001999371-25-014216.json
- Plain text: https://secwatch.observer/filing/0001999371-25-014216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.